Home / Investors Information / EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer Read more about EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies Read more about EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies Vanderbilt Announces Participation in Ablatherm Study Read more about Vanderbilt Announces Participation in Ablatherm Study EDAP Launches Enhanced Communication Plans at SIU Paris Congress Read more about EDAP Launches Enhanced Communication Plans at SIU Paris Congress EDAP TMS S.A. Closes $20 Million Placement to Fully Fund Its U.S. Clinical Studies Read more about EDAP TMS S.A. Closes $20 Million Placement to Fully Fund Its U.S. Clinical Studies EDAP's Ablatherm-HIFU Recognized as the Only HIFU Robotic Option At Global Urology Meeting Read more about EDAP's Ablatherm-HIFU Recognized as the Only HIFU Robotic Option At Global Urology Meeting EDAP Launches Ablatherm-HIFU RPP Service At First South African Site Read more about EDAP Launches Ablatherm-HIFU RPP Service At First South African Site EDAP Announces Third Quarter Results Conference Call Read more about EDAP Announces Third Quarter Results Conference Call EDAP TMS S.A. 2007 Third Quarter HIFU Revenues Increase Read more about EDAP TMS S.A. 2007 Third Quarter HIFU Revenues Increase EDAP Ablatherm Clinical Study Begins At Vanderbilt Medical Read more about EDAP Ablatherm Clinical Study Begins At Vanderbilt Medical Pagination First page « First Previous page ‹ Previous … Page 48 Page 49 Page 50 Page 51 Page 52 Current page 53 Page 54 Page 55 Page 56 Next page Next › Last page Last » Subscribe to
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer Read more about EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies Read more about EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies
Vanderbilt Announces Participation in Ablatherm Study Read more about Vanderbilt Announces Participation in Ablatherm Study
EDAP Launches Enhanced Communication Plans at SIU Paris Congress Read more about EDAP Launches Enhanced Communication Plans at SIU Paris Congress
EDAP TMS S.A. Closes $20 Million Placement to Fully Fund Its U.S. Clinical Studies Read more about EDAP TMS S.A. Closes $20 Million Placement to Fully Fund Its U.S. Clinical Studies
EDAP's Ablatherm-HIFU Recognized as the Only HIFU Robotic Option At Global Urology Meeting Read more about EDAP's Ablatherm-HIFU Recognized as the Only HIFU Robotic Option At Global Urology Meeting
EDAP Launches Ablatherm-HIFU RPP Service At First South African Site Read more about EDAP Launches Ablatherm-HIFU RPP Service At First South African Site
EDAP Announces Third Quarter Results Conference Call Read more about EDAP Announces Third Quarter Results Conference Call
EDAP TMS S.A. 2007 Third Quarter HIFU Revenues Increase Read more about EDAP TMS S.A. 2007 Third Quarter HIFU Revenues Increase
EDAP Ablatherm Clinical Study Begins At Vanderbilt Medical Read more about EDAP Ablatherm Clinical Study Begins At Vanderbilt Medical
